China NMPA Drug Inspection - Hainan Huipusen Pharmaceutical Biotechnology Co., Ltd. - Ozagrel sodium for injection
China NMPA drug inspection for Hainan Huipusen Pharmaceutical Biotechnology Co., Ltd. published August 20, 2020. Drug: Ozagrel sodium for injection. On August 20, 2020, China’s National Medical Products Administration (NMPA) issued Announcement No. 55, identifying 25 b
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Hainan Huipusen Pharmaceutical Biotechnology Co., Ltd. published August 20, 2020. Drug: Ozagrel sodium for injection. On August 20, 2020, China’s National Medical Products Administration (NMPA) issued Announcement No. 55, identifying 25 b
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox